Nevirapine oral susp. 10mg/ml/BOT-100ml
NOTE: The description below is for a standard product. It is notspecific to patent status and pricing policies that may apply at countrylevel. This information is available on request from Supply Division:Contact: email@example.com
Nevirapine oral suspension 10mg/ml, bottle pack of 100ml with oraldispensing syringe
Each 5ml contains Nevirapine Hemihydrate 51.75mg equivalent toNevirapine 50mg.
Pack comes with oral dispensing syringe.
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Standard shelf life
The product should be used within 4 weeks of opening.
Other available formulations
The product may also be available in other formulations, pack sizes, orin combinations with other ARVs.
Guidelines for use
For more details, please see WHO treatment guidelines
and WHO Essential Medicines Library http://www.who.int/emlib/ or yourregional/national guidelines.
Details about paediatric dosage schemes can be found at www.who.int/hiv/topics/paediatric/en/
WHO generic tool for assessing paediatric ARV dosing
Management of HIV infection in combination with at least two otherantiretroviral drugs. By mouth (oral), PO
Prevention of mother-to-child transmission in HIV-infected patients.
Do not store above 30ºC (86ºF). Do not freeze
Store in a tightly closed container.
Keep protected from light
Keep out of reach and sight of children
Note: Use suspension within 1 (one) month after opening
Shake the suspension gently before administration
The entire dose, especially for volumes less than 5ml, should bemeasured and administered accurately using a dose measuring oral syringeor cup. If a measuring cup is used, rinse it with a small amount ofdrinking water and administer the rinse to the patient.
May be taken with or without regard to food.
For latest updates check the list of Prequalified Medicines on the WHOwebsite Prequalification Programme. apps.who.int/prequal/
For latest updates check the list of USFDA approved and tentativelyapproved items on the USFDA website.